Literature DB >> 34586338

Comparison of Long-term Clinical Outcomes of Skeletonized vs Pedicled Internal Thoracic Artery Harvesting Techniques in the Arterial Revascularization Trial.

Mario Gaudino1, Katia Audisio1, Mohamed Rahouma1, David Chadow1, Gianmarco Cancelli1, Giovanni J Soletti1, Alastair Gray2, Belinda Lees3, Stephen Gerry4, Umberto Benedetto5, Marcus Flather6, David P Taggart3.   

Abstract

Importance: Recent evidence has suggested that skeletonization of the internal thoracic artery (ITA) is associated with worse clinical outcomes in patients undergoing coronary artery bypass surgery (CABG). Objective: To compare the long-term clinical outcomes of skeletonized and pedicled ITA for CABG. Design, Setting, and Participants: The Arterial Revascularization Trial (ART) was a 2-group, multicenter trial comparing the use of a bilateral ITA vs a single ITA for CABG at 10 years. Patients in the ART trial were stratified by ITA harvesting technique: skeletonized vs pedicled. Data were collected from June 2004 to December 2017, and data were analyzed from June to July 2021. Interventions: In this analysis, the 10-year clinical outcomes were compared between patients who received skeletonized vs pedicled ITAs. Main Outcomes and Measures: The primary outcome was all-cause mortality. The secondary outcomes were a composite of major adverse cardiac events (MACE) including all-cause mortality, myocardial infarction, and repeated revascularization and a composite including MACE and sternal wound complication (SWC). Cox regression and propensity score matching were used.
Results: Of 2161 included patients, 295 (13.7%) were female, and the median (interquartile range) age was 65.0 (58.0-70.0) years. At 10 years, the risk of all-cause mortality was not significantly different between the pedicled and skeletonized groups (hazard ratio [HR], 1.12; 95% CI, 0.92-1.36; P = .27). However, the long-term risks of the secondary outcomes were significantly higher in the skeletonized group compared with the pedicled group (MACE: HR, 1.25; 95% CI, 1.06-1.47; P = .01; MACE and SWC: HR, 1.22; 95% CI, 1.05-1.43; P = .01). The difference was not seen when considering only patients operated on by surgeons who enrolled 51 patients or more in the trial (MACE: HR, 1.07; 95% CI, 0.82-1.39; P = .62; MACE and SWC: HR, 1.04; 95% CI, 0.80-1.34; P = .78). Conclusions and Relevance: While the long-term survival of patients was not different between groups, the rate of adverse cardiovascular events was consistently higher in the skeletonized group and the difference was associated with surgeon-related factors. Further evidence on the outcome of skeletonized ITA is needed.

Entities:  

Mesh:

Year:  2021        PMID: 34586338      PMCID: PMC8482293          DOI: 10.1001/jamacardio.2021.3866

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   30.154


  3 in total

1.  Prognostic significance of postoperative loss of skeletal muscle mass in patients underwent coronary artery bypass grafting.

Authors:  Zi-Le Shen; Zhang Liu; Peng Zhang; Wei-Zhe Chen; Wen-Xi Dong; Wen-Hao Chen; Feng Lin; Wang-Fu Zang; Xia-Lin Yan; Zhen Yu
Journal:  Front Nutr       Date:  2022-09-02

2.  Long-term survival of single versus bilateral internal mammary artery grafting in patients under 70.

Authors:  Armando Abreu; José Máximo; Adelino Leite-Moreira
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-09-09

3.  Robotic coronary revascularization in Europe, state of art and future of EACTS-endorsed Robotic Cardiothoracic Surgery Taskforce.

Authors:  Matto Pettinari; Monica Gianoli; Meindert Palmen; Stepan Cerny; Burak Onan; Sandeep Singh; Patrique Segers; Cengiz Bolcal; Cem Alhan; Emiliano Navarra; Herbert De Praetere; Jan Vojacek; Theodor Cebotaru; Paul Modi; Fabien Doguet; Ulrich Franke; Ahmed Ouda; Ludovic Melly; Ghislain Malapert; Louis Labrousse; Alfonso Agnino; Tine Philipsen; Jean-Luc Jansens; Thierry Folliguet; Daniel Pereda; Francesco Musumeci; Piotr Suwalski; Koen Cathenis; Frank Van Praet; Johannes Bonatti; Wouter Oosterlinck
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-09-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.